COVID-19-Endothelial Axis and Coronary Artery Bypass Graft Patency: a Target for Therapeutic Intervention?

Topal G., Loesch A., Dashwood M. R.

BRAZILIAN JOURNAL OF CARDIOVASCULAR SURGERY, cilt.35, sa.5, ss.757-763, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 5
  • Basım Tarihi: 2020
  • Doi Numarası: 10.21470/1678-9741-2020-0303
  • Dergi Adı: BRAZILIAN JOURNAL OF CARDIOVASCULAR SURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.757-763
  • Anahtar Kelimeler: COVID-19, SARS Virus, Coronary Artery Bypass Graft Surgery, Saphenous Vein, Endothelial Dysfunction, Vascular Inflammation, ENDOTHELIUM-DEPENDENT CONTRACTIONS, SCANNING-ELECTRON-MICROSCOPY, SAPHENOUS-VEIN, VASA VASORUM, VASCULAR-TONE, DYSFUNCTION, ACTIVATION, HYPOTHESIS, PREVENTION, COVID-19
  • İstanbul Üniversitesi Adresli: Evet

Özet

It has been reported that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection induces endothelial inflammation, therefore facilitating the progression of endothelial and vascular dysfunction in coronavirus disease 2019 (COVID-19) patients. Coronary artery bypass grafting (CABG) involves mainly the use of the saphenous vein (SV) and internal mammary artery as graft material in the stenosed coronary arteries. Unfortunately, graft patency of the SV is low due to endothelial dysfunction and inflammation. We propose that SARS-CoV-2 might cause vascular inflammation, endothelial dysfunction, and thrombosis in coronary artery bypass graft vessels by binding angiotensin-converting enzyme 2 receptor. Therefore, in this Special Article, we consider the potential influence of COVID-19 on the patency rates of coronary artery bypass graft vessels, mainly with reference to the SV. Moreover, we discuss the technique of SV graft harvesting and the therapeutic potential of focusing on endothelial dysfunction, vascular inflammation, and thrombosis for protecting coronary artery bypass grafts in COVID-19 infected CABG patients.